Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Last Updated: March 29, 2023

Details for Patent: 7,829,120

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,829,120 protect, and when does it expire?

Patent 7,829,120 protects OLEPTRO and is included in one NDA.

This patent has forty-six patent family members in twenty-five countries.

Summary for Patent: 7,829,120
Title:Trazodone composition for once a day administration
Abstract:The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
Inventor(s): Gervais; Sonia (Laval, CA), Smith; Damon (Saint-Laurent, CA), Rahmouni; Miloud (Pierrefonds, CA), Contamin; Pauline (Magny En Vexin, FR), Ouzerourou; Rachid (Anjou, CA), Ma; My Linh (Saint-Laurent, CA), Ferrada; Angela (Montreal, CA), Soulhi; Fouzia (Dollard-des-Ormeaux, CA)
Assignee: Labopharm Inc. (Quebec, CA) Labopharm Europe Limited (Dublin, IE) Labopharm (Barbados) Limited (St. Michael, BB)
Application Number:11/519,194
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Delivery; Use; Formulation;

Drugs Protected by US Patent 7,829,120

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-001 Feb 2, 2010 DISCN Yes No See Plans and Pricing See Plans and Pricing Y METHOD OF TREATING DEPRESSION See Plans and Pricing
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-002 Feb 2, 2010 DISCN Yes No See Plans and Pricing See Plans and Pricing Y METHOD OF TREATING DEPRESSION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.